<DOC>
	<DOC>NCT01241591</DOC>
	<brief_summary>To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.</brief_summary>
	<brief_title>A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris); Have plaquetype psoriasis covering at least 10% of total body surface area Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis Nonplaque or drug induced forms of psoriasis Cannot discontinue current systemic and/or topical therapies for the treatment of psoriasis Cannot discontinue phototherapy Any uncontrolled significant medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CP-690,550</keyword>
	<keyword>Etanercept</keyword>
	<keyword>Moderate</keyword>
	<keyword>Severe</keyword>
	<keyword>Chronic</keyword>
	<keyword>Plaque</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>Tofacitinib</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>OPT Compare</keyword>
	<keyword>OPT</keyword>
	<keyword>head-to-head</keyword>
	<keyword>non-inferiority</keyword>
	<keyword>Psoriasis vulgaris</keyword>
	<keyword>short-term</keyword>
	<keyword>Itch</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Plaque psoriasis</keyword>
	<keyword>DLQI</keyword>
</DOC>